BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders.
It is a $10.6B healthcare company. Revenue grew 11.2% over the last year, and it keeps 2¢ of every dollar of sales as profit. It trades at 145.4× earnings — around the middle of its own history.
- Website
- biomarin.com
- Location
- Novato, CA
- Employees
- 3 221
- Sector
- Healthcare
- Founded
- 1997
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Growth, Profitability, Health and Moat lag behind.
Valuation52
- P/E vs own history55th pct · 12/25
- FCF yield7.0% · 20/25
- P/S3.1x · 20/25
- EV/EBITDA58.7x · 0/25
Growth45
- Revenue CAGR14.9% · 20/25
- Net income CAGRn/a · 0/25
- EPS CAGR ~5Y-17.0% · 0/25
- Fwd implied growth829.5% · 25/25
Profitability21
- ROIC7.7% · 5/25
- ROE1.2% · 5/25
- Net margin2.1% · 6/25
- Operating margin4.4% · 5/25
Health35
- Altman Z1.70 · 10/25
- Current ratio2.39 · 25/25
- Interest coverage-21.2x · 0/25
- Net cash / debtn/a · 0/25
Quality65
- Piotroski F5/9 · 15/25
- Beneish M-2.59 · 25/25
- FCF conversion1012% · 25/25
- Margin stabilityσ 97.1% · 0/25
Moat30
- ROIC >12% years0/10 yrs · 0/25
- Median gross margin78.8% · 25/25
- FCF-positive years5/10 yrs · 5/25
- Worst-year net marginworst -56.4% · 0/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2025AcquisitionBioMarin agreed to acquire Amicus Therapeutics for $4.8 billion
- FY2021FinancialPositive free cash flow every year since5-year streak
- FY2020FinancialTurned profitable$859M net income after a loss year
- FY2020FinancialBest year on record$859M net income
- FY2016FinancialRevenue already above $1B$1.12B in first reported year
- 2014AcquisitionBioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the…
- 2012AcquisitionBioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on…
- 2010AcquisitionBioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage…
- 2009AcquisitionBioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley)
- 2002AcquisitionBioMarin acquired Glyko Biomedical
- 1999IPODenison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999
- 1997FoundedBioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (79.6%)
- Revenue growing 11.2% year over year
- Strong cash conversion — FCF is 21.7% of revenue
Watch-outs
- Altman Z-Score 1.70 — elevated financial-distress risk
- Thin interest coverage (-21.2×)
- Loss-making in 5 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+11.2% YoY
- Profitable — makes more than it spends$73.0M TTM
- Profit growing — earnings are higher than last year+33.1% YoY
- Generates cash — cash left after running and investing$738M TTM
- Debt under control — could handle its obligationscurrent ratio 2.39
- Established company — not a micro-cap — lower blow-up risk$10.6B market cap
- Not printing shares — share count not ballooning — you keep your slice+3.0% shares over ~5y
- Proven track record — years of profitability behind it5/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 1.7 — distress
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsP/E 145.4
Peer comparisonBioMarin Pharmaceuticals Inc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| BMRN this company | $10.6B | 145.4 | +11.2% | 2.1% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: BMRN vs LLY · BMRN vs JNJ · BMRN vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/BMRN
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of BMRN on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $54.80 · market cap $10.6B.